Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Amgen to Acquire Rodeo Therapeutics Corp.

03/30/2021 | 04:47pm EDT

By Stephen Nakrosis

Amgen Inc. on Tuesday said it agreed to acquire privately-held Rodeo Therapeutics Corp.

Amgen said the biopharmaceutical company "develops small-molecule therapies designed to promote regeneration and repair of multiple tissues."

The deal will see Amgen "acquire all outstanding shares of Rodeo in exchange for a $55 million upfront payment as well as future contingent milestone payments potentially worth up to an additional $666 million in cash," Amgen said.

The deal has received the approval of Rodeo's shareholders and board.

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

03-30-21 1646ET

All news about AMGEN INC.
05:01aDECODE GENETICS : Predicting the probability of death
PR
06/17AMGENá : Showing the Way
PU
06/15AMGENá : Acclaimed Makeup Artist Allan Avendaño and Otezla Patient, Sarah, Provi..
PU
06/15ACCLAIMED MAKEUP ARTIST ALLAN AVENDA : Provides INSIDE LOOK At Life With Plaque ..
PR
06/14Amplitude Healthcare Target Jasper Gets Key FDA Designations
DJ
06/10AMGENá : Registration is Now Open for Medical Devices and IVD Conference 2021
AQ
06/09AMGENá : CEO Bob Bradway Stresses Value of Biopharmaceutical Innovation at Finan..
PU
06/08FDA Approval of New Alzheimer's Drug May Boost Prospects of Other Treatments
DJ
06/08ANALYST RECOMMENDATIONS : Amgen, Biogen, Halfords, J Sainsbury, Uber...
06/07AMGENá : Innovation for Patients at Heart of European Hematology Association Con..
PU
More news
Financials (USD)
Sales 2021 26 016 M - -
Net income 2021 6 970 M - -
Net Debt 2021 20 957 M - -
P/E ratio 2021 20,9x
Yield 2021 2,88%
Capitalization 138 B 138 B -
EV / Sales 2021 6,12x
EV / Sales 2022 5,74x
Nbr of Employees 24 300
Free-Float 99,8%
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 249,79 $
Last Close Price 240,76 $
Spread / Highest target 23,8%
Spread / Average Target 3,75%
Spread / Lowest Target -23,2%
EPS Revisions
Managers and Directors
NameTitle
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Executive Vice President-Research & Development
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN INC.4.71%138 330
JOHNSON & JOHNSON4.98%435 090
ROCHE HOLDING AG12.75%328 768
PFIZER, INC.7.25%220 997
NOVARTIS AG2.73%210 424
ABBVIE INC.7.23%202 939